modelFlucytosine
Extends from Pharmacolibrary.Drugs.ATC.J.J02AX01.
Information
| name: | Flucytosine | |
| ATC code: | J02AX01 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.6 | L |
| clearance: | 1.5 | mL/min/kg |
| other parameters in model implementation | ||
Flucytosine is an antifungal medication used primarily in combination with other agents (commonly amphotericin B) for the treatment of severe systemic fungal infections such as cryptococcal meningitis and candidiasis. It acts as a pyrimidine analog, interfering with fungal DNA and RNA synthesis. Flucytosine is approved by regulatory agencies and remains in use today, mainly for specific difficult-to-treat infections and susceptible organisms.
Pharmacokinetics
Pharmacokinetic data for orally administered flucytosine in adult patients with normal renal function.
References
Kim, HY, et al., & Alffenaar, JW (2020). Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. Frontiers in pharmacology 11 894–None. DOI:10.3389/fphar.2020.00894 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32595511
Dupont, B (2001). [Choice and use of antifungal drugs]. La Revue du praticien 51(7) 752–757. PUBMED:https://pubmed.ncbi.nlm.nih.gov/11387672
Hayashi, Y, et al., & Yamada, Y (1995). [Study of serial bronchoalveolar lavage in patients with aspergilloma: cell reaction at the affected sites and penetration of miconazole and flucytosine into the lesion]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 69(5) 517–523. DOI:10.11150/kansenshogakuzasshi1970.69.517 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7602184
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)